Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients: A therapeutic window relationship

S. Ulrich, G. Northoff, C. Wurthmann, G. Partscht, U. Pester, H. Herscu, F. P. Meyer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

In a prospective, open clinical study, the relationship between serum levels of amitriptyline (At) and nortriptyline (Nt) and the therapeutic effect after 6 weeks of treatment was investigated. Serum levels were measured by gas-liquid chromatography and the therapeutic effect was assessed by the Hamilton Depression Rating Scale (HAMD) and the Clinical Global Impression Scale (CGI). A number of 25 non-delusional, moderate to severely depressed inpatients were included. A therapeutic window relationship was detected by means of regression analysis (quadratic model). Low and high serum levels were associated with low therapeutic effect. In an intermediate range, the probability of good therapeutic effect was increased. This relationship reached significance for the serum levels of At(p <0.05) and a trend for the sum of serum levels of At and Nt (p <0.1). As expressed by the regression coefficient r2, about 25% to 35% of the variability of therapeutic effect was explained by serum levels. Dichotomized data sets according to limits of final values of HAMD and CGI as well as limits of a therapeutic window of 70 ng/ml and 200 ng/ml (sum of At and Nt) revealed significant differences by means of Fisher's exact test (p <0.05). Furthermore, increased ratios of serum level of Nt per serum level of At were found to be associated with decreased therapeutic effect. Thus, the present data support the existence of a therapeutic window of serum levels of At in depression. Also taking into account other reports, this therapeutic window can be defined as being between about 70 and 220 ng/ml. The assay of serum levels of At can be used to lower the risk of unsatisfactory therapeutic outcome.

Original languageEnglish
Pages (from-to)33-40
Number of pages8
JournalPharmacopsychiatry
Volume34
Issue number1
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Amitriptyline
Therapeutic Uses
Nortriptyline
Serum
Therapeutics
Gas Chromatography
Inpatients
Regression Analysis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients : A therapeutic window relationship. / Ulrich, S.; Northoff, G.; Wurthmann, C.; Partscht, G.; Pester, U.; Herscu, H.; Meyer, F. P.

In: Pharmacopsychiatry, Vol. 34, No. 1, 2001, p. 33-40.

Research output: Contribution to journalArticle

Ulrich, S. ; Northoff, G. ; Wurthmann, C. ; Partscht, G. ; Pester, U. ; Herscu, H. ; Meyer, F. P. / Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients : A therapeutic window relationship. In: Pharmacopsychiatry. 2001 ; Vol. 34, No. 1. pp. 33-40.
@article{ce29a0323e6545c39cd25fd76100b6f8,
title = "Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients: A therapeutic window relationship",
abstract = "In a prospective, open clinical study, the relationship between serum levels of amitriptyline (At) and nortriptyline (Nt) and the therapeutic effect after 6 weeks of treatment was investigated. Serum levels were measured by gas-liquid chromatography and the therapeutic effect was assessed by the Hamilton Depression Rating Scale (HAMD) and the Clinical Global Impression Scale (CGI). A number of 25 non-delusional, moderate to severely depressed inpatients were included. A therapeutic window relationship was detected by means of regression analysis (quadratic model). Low and high serum levels were associated with low therapeutic effect. In an intermediate range, the probability of good therapeutic effect was increased. This relationship reached significance for the serum levels of At(p <0.05) and a trend for the sum of serum levels of At and Nt (p <0.1). As expressed by the regression coefficient r2, about 25{\%} to 35{\%} of the variability of therapeutic effect was explained by serum levels. Dichotomized data sets according to limits of final values of HAMD and CGI as well as limits of a therapeutic window of 70 ng/ml and 200 ng/ml (sum of At and Nt) revealed significant differences by means of Fisher's exact test (p <0.05). Furthermore, increased ratios of serum level of Nt per serum level of At were found to be associated with decreased therapeutic effect. Thus, the present data support the existence of a therapeutic window of serum levels of At in depression. Also taking into account other reports, this therapeutic window can be defined as being between about 70 and 220 ng/ml. The assay of serum levels of At can be used to lower the risk of unsatisfactory therapeutic outcome.",
author = "S. Ulrich and G. Northoff and C. Wurthmann and G. Partscht and U. Pester and H. Herscu and Meyer, {F. P.}",
year = "2001",
doi = "10.1055/s-2001-15207",
language = "English",
volume = "34",
pages = "33--40",
journal = "Pharmacopsychiatry",
issn = "0176-3679",
publisher = "Georg Thieme Verlag",
number = "1",

}

TY - JOUR

T1 - Serum levels of amitriptyline and therapeutic effect in non-delusional moderately to severely depressed in-patients

T2 - A therapeutic window relationship

AU - Ulrich, S.

AU - Northoff, G.

AU - Wurthmann, C.

AU - Partscht, G.

AU - Pester, U.

AU - Herscu, H.

AU - Meyer, F. P.

PY - 2001

Y1 - 2001

N2 - In a prospective, open clinical study, the relationship between serum levels of amitriptyline (At) and nortriptyline (Nt) and the therapeutic effect after 6 weeks of treatment was investigated. Serum levels were measured by gas-liquid chromatography and the therapeutic effect was assessed by the Hamilton Depression Rating Scale (HAMD) and the Clinical Global Impression Scale (CGI). A number of 25 non-delusional, moderate to severely depressed inpatients were included. A therapeutic window relationship was detected by means of regression analysis (quadratic model). Low and high serum levels were associated with low therapeutic effect. In an intermediate range, the probability of good therapeutic effect was increased. This relationship reached significance for the serum levels of At(p <0.05) and a trend for the sum of serum levels of At and Nt (p <0.1). As expressed by the regression coefficient r2, about 25% to 35% of the variability of therapeutic effect was explained by serum levels. Dichotomized data sets according to limits of final values of HAMD and CGI as well as limits of a therapeutic window of 70 ng/ml and 200 ng/ml (sum of At and Nt) revealed significant differences by means of Fisher's exact test (p <0.05). Furthermore, increased ratios of serum level of Nt per serum level of At were found to be associated with decreased therapeutic effect. Thus, the present data support the existence of a therapeutic window of serum levels of At in depression. Also taking into account other reports, this therapeutic window can be defined as being between about 70 and 220 ng/ml. The assay of serum levels of At can be used to lower the risk of unsatisfactory therapeutic outcome.

AB - In a prospective, open clinical study, the relationship between serum levels of amitriptyline (At) and nortriptyline (Nt) and the therapeutic effect after 6 weeks of treatment was investigated. Serum levels were measured by gas-liquid chromatography and the therapeutic effect was assessed by the Hamilton Depression Rating Scale (HAMD) and the Clinical Global Impression Scale (CGI). A number of 25 non-delusional, moderate to severely depressed inpatients were included. A therapeutic window relationship was detected by means of regression analysis (quadratic model). Low and high serum levels were associated with low therapeutic effect. In an intermediate range, the probability of good therapeutic effect was increased. This relationship reached significance for the serum levels of At(p <0.05) and a trend for the sum of serum levels of At and Nt (p <0.1). As expressed by the regression coefficient r2, about 25% to 35% of the variability of therapeutic effect was explained by serum levels. Dichotomized data sets according to limits of final values of HAMD and CGI as well as limits of a therapeutic window of 70 ng/ml and 200 ng/ml (sum of At and Nt) revealed significant differences by means of Fisher's exact test (p <0.05). Furthermore, increased ratios of serum level of Nt per serum level of At were found to be associated with decreased therapeutic effect. Thus, the present data support the existence of a therapeutic window of serum levels of At in depression. Also taking into account other reports, this therapeutic window can be defined as being between about 70 and 220 ng/ml. The assay of serum levels of At can be used to lower the risk of unsatisfactory therapeutic outcome.

UR - http://www.scopus.com/inward/record.url?scp=0035141382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035141382&partnerID=8YFLogxK

U2 - 10.1055/s-2001-15207

DO - 10.1055/s-2001-15207

M3 - Article

C2 - 11229620

AN - SCOPUS:0035141382

VL - 34

SP - 33

EP - 40

JO - Pharmacopsychiatry

JF - Pharmacopsychiatry

SN - 0176-3679

IS - 1

ER -